相关实验视频

Updated: Sep 9, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

使用计算方法揭示DYRK激酶家族异形选择性机制的生物物理基础

K D Ursal¹, P Kar¹

¹Mehta Family School of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, India.

SAR and QSAR in environmental research

|September 4, 2025

概括

美国食品和药物管理局批准的药物Abemaciclib对DYRK1B的结合比DYRK1A更强,因此它作为选择性DYRK1A抑制剂的使用具有挑战性. 这项研究揭示了影响DYRK家族激酶选择性的关键分子相互作用.

科学领域:

生物化学
结构生物学
药理学

背景情况:

双特异氨酸酸化调节激酶 (DYRKs) 对细胞生长和神经发育至关重要.
DYRK失调与唐氏综合征和各种癌症有关.
在高度相似的异型中实现DYRK1A的选择性抑制是一个主要的治疗挑战.

研究的目的:

对DYRK激酶家族进行评估,以评估FDA批准的CDK4/ 6抑制剂Abemaciclib的异型选择性.
阐明Abemaciclib在DYRK家族中的结合偏好的分子基础.
为设计新的选择性DYRK抑制剂提供见解.

主要方法:

使用了包括分子对接和分子动力学模拟在内的计算方法.
用分子力学Poisson-Boltzmann表面积 (MM/PBSA) 方法进行结合能量的计算.
进行统计分析以验证计算结果.

主要成果:

对DYRK1B表现出最强的结合亲和力,其次是DYRK1A,DYRK4,DYRK3和DYRK2.
对DYRK1B的增强选择性归因于优异的范德瓦尔斯和静电相互作用.
特定的氨基酸残留物,包括Leu241,Phe170,Glu239和His285,被确定为差异结合的关键.

结论:

阿贝马西克利布对DYRK1B的结合优于DYRK1A,这表明其作为选择性DYRK1A抑制剂的使用存在局限性.
了解保存和特定相互作用有助于合理设计DYRK异形选择性抑制剂.
这项研究为开发针对DYRK相关疾病的向治疗提供了基础.

关键词:

DYRKs家族癌症分子动力学神经系统疾病治疗性亲和力

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...